Multidimensional Issues in Type 2 Diabetes
Looking Beyond Hemoglobin A1c
Meeting Slides
Clinical Practice Guidelines
Standards of medical care in diabetes—2020.
American Diabetes Association. Diabetes Care. 2020;43(suppl 1):S1-S212.
2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Das SR, Everett BM, Birtcher KK, et al. J Am Coll Cardiol. 2018;72(24):3200-3223.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract. 2019;25(1):69-100.
Patient and Caregiver Resources
American Association of Diabetes Educators
American Diabetes Association
Centers for Disease Control and Prevention: Diabetes Education Materials
National Diabetes Education Program
Suggested Readings
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Cannon CP, McGuire DK, Pratley R, et al. Am Heart J. 2018;206:11-23.
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
DeFronzo RA, Norton L, Abdul-Ghani M. Nat Rev Nephrol. 2017;13(1):11-26.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Lancet. 2013;382(9889):339-352.
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Inzucchi SE, Zinman B, Wanner C, et al. Diab Vasc Dis Res. 2015;12(2):90-100.
Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.
King RJ, Grant PJ. Herz. 2016;41(3):184-192.
Diabetes mellitus and heart failure.
Lehrke M, Marx N. Am J Cardiol. 2017; 120(suppl 1):S37-S47.
Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.
Mahaffey KW, Jardine MJ, Bompoint S, et al. Circulation. 2019;140(9):739-750.
Dapagliflozin in patients with heart failure and reduced ejection fraction.
McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med. 2019. [Epub ahead of print]
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O, Wiviott SD, Cahn A, et al. Lancet Diabetes Endocrinol. 2019;7(8):606-617.
Canagliflozin and cardiovascular and renal events in type 2 diabetes.
Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med. 2017;377(7):644-657.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019;380(24):2295-2306.
Diabetic kidney disease.
Thomas MC, Brownlee M, Susztak K, et al. Nat Rev Dis Primers. 2015;1:15018.
Diabetic kidney disease: pathophysiology and therapeutic targets.
Toth-Manikowski S, Atta MG. J Diabetes Res. 2015;2015:697010.
SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome.
van Bommel EJ, Muskiet MH, Tonneijck L, et al. Clin J Am Soc Nephrol. 2017;12(4):700-710.
Empagliflozin and progression of kidney disease in type 2 diabetes.
Wanner C, Inzucchi SE, Lachin JM, et al. N Engl J Med. 2016;375(4):323-334.
Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
Wiviott SD, Raz I, Bonaca MP, et al. N Engl J Med. 2019;380(4):347-357.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA, Wiviott SD, Raz I, et al. Lancet. 2019;393(10166):31-39.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128.
Interactive PresentationConnecting T2DM Pathophysiology, Comorbidities, and SGLT2 Inhibitors
Presented by Derek LeRoith, MD, PhD
Debates and Discussions Around Cardiovascular and Renal Outcomes
Looking Beyond Hemoglobin A1c
Looking Beyond Hemoglobin A1c
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Individualizing Evidence-Based Care
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Implications for PCSK9 Inhibitors in Clinical Practice
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Reducing LDL-C and a Lifetime of Cardiovascular Risk
